|
|
|
|
|
by aeberbach
4403 days ago
|
|
"Gleevec became a breakthrough, helping almost every patient with a particular rare blood cancer, chronic myelogenous leukemia. Patients stay on it for years, and it is so valuable that Novartis has quadrupled its annual price from $24,000 per year in 2001 to more than $90,000 today. Even the stingiest insurers pay, though some patients get it free." I am also in a country where you don't have to choose between pay or die, and I'm thankful for that. Seeing this kind of thing in print certainly makes you look twice and appreciate what you have. |
|